Skip to main content

Headlands Research Further Expands its Leading Clinical Research Site Network by Acquiring Peninsula Research Associates

Written by Customer Service on . Posted in Mergers And Acquisitions.

SAN FRANCISCO, June 30, 2022 (GLOBE NEWSWIRE) — Headlands Research announced today the acquisition of Peninsula Research Associates (PRA) of Rolling Hills, CA, continuing the growth of its leading integrated network of clinical trial sites. Terms of the transaction were not disclosed.

The addition of PRA augments Headlands’ clinical research capabilities in the allergy and asthma therapeutic areas, as well as extends its expertise into pediatric studies. In addition, PRA has a well-earned representation as a leading clinical research site for conducting high-quality research studies in the vaccine space, which is a Headlands’ Center of Excellence.

The acquisition of PRA advances Headlands’ mission of profoundly impacting the clinical trial process as well as extending its global network of clinical trial sites further within California, beyond its current San Diego and Riverside locations, as well as its headquarters in the San Francisco Bay Area.

“We are extremely excited to welcome Dr. Lawrence Sher and PRA’s outstanding research team to the Headlands network,” said Mark Blumling, CEO and Founder of Headlands Research. “Together, we look forward to significantly expanding research activity and improving the lives of clinical trial participants throughout Southern California.”

About Headlands Research

Headlands Research is a globally integrated clinical trial site organization with a mission to profoundly change the clinical trials process. Its group of exceptional sites focuses on large volume recruitment of diverse and specialty patient populations while delivering the highest quality data. Headlands Research’s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse patients through its site databases and physician partnerships. Based in San Francisco and backed by KKR & Co. Inc (NYSE: KKR), Headlands aims to ensure that high quality therapeutics are made available to patients who can benefit from them. Headlands Research has successfully completed more than 5000 clinical trials. Additional information about the company is available at www.headlandsresearch.com

Media Contact:
Lauren Chazal
Headlands Research
media@headlandsresearch.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.